All In Biotech

Drug Trial Radar · NCT04424290

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

A First-in Human Trial to Study Safety and Tolerability of Single Rising Intravitreal dOses (Open Label, Non-randomized, Uncontrolled) and in Addition the Early Biological Response of Multiple intravitReal Dosing (Single-masked, raNdomized, Sham-controlled) of BI 764524 in panretinaL Photocoagulation (PRP) Treated proLiferative Diabetic Retinopathy (PDR) Patients With Diabetic Macular Ischemia (DMI) - the HORNBILL Study

Last checked: Nov 20, 2026Latest source record: May 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

45

Actual

Start

Jun 12, 2020

Primary completion

Apr 28, 2023

Study completion Apr 28, 2023

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jun 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study. The laser treatment is called panretinal photocoagulation. The purpose of the study is to find out how well different doses of a medicine called BI 764524 are tolerated. BI 764524 is injected into the eye. The study has 2 parts. In the first part, participants get different doses of BI 764524 only once. Participants are in the first part for about 5 months and visit the study site about 8 times. In the second part, participants are put into different groups by chance. Some participants get BI 764524 injections every 4 weeks. Other participants get sham injections every 4 weeks. A sham injection means that it is not a real injection and contains no medicine. Participants cannot tell whether they get the real injection or a sham injection. For the second part, participants are in the study for about 7 months. During this time, they visit the study site about 7 times. In this study, BI 764524 is given to humans for the first time. The doctors compare how well people tolerate the BI 764524 injections and the sham injections. The doctors also regularly check the general health of the participants.

Conditions

  • Diabetic Retinopathy

Interventions

  • BI 764524Drug

    BI 764524

  • Sham control of BI 764524Drug

    Sham control of BI 764524

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Single-rising Dose (SRD) Part - The Number of Patients With Dose Limiting Events (DLEs) From Drug Administration Until Day 8Time frame: From drug administration (day 1) till day 8, Up to 7±2 days.
  2. Multiple Dosing (MD) Part - the Number of Patients With Drug-related Adverse Events (AEs) From Drug Administration Until End of Trial.Time frame: From drug administration (day 1) till End of Trial, up to 23 weeks.

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • Trinity Research

    Dothan, Alabama

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • Stanford University Medical Center

    Palo Alto, California

  • Florida Retina Institute

    Orlando, Florida

  • Raj K. Maturi, MD PC

    Carmel, Indiana

  • Joslin Diabetes Center

    Boston, Massachusetts

  • Long Island Vitreoretinal Consultants

    Great Neck, New York

  • New York Eye and Ear Infirmary of Mount Sinai

    New York, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • Austin Research Center for Retina, PLLC

    Austin, Texas

  • Retina Consultants of Texas

    Bellaire, Texas

  • Valley Retina Institute, PA

    McAllen, Texas

  • Retina Consultants of Texas

    The Woodlands, Texas

  • Bradford Royal Infirmary

    Bradford, United Kingdom

  • Bristol Eye Hospital

    Bristol, United Kingdom

  • Southend University Hospital

    Essex, United Kingdom

  • Gloucestershire Royal Hospital

    Gloucester, United Kingdom

  • Moorfields Eye Hospital

    London, United Kingdom

  • Sunderland Eye Infirmary

    Sunderland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.